Skip to main content

Bate Kenneth's Form 4 filing

Madrigal Pharmaceuticals, Inc. (MDGL) · filed Nov 7, 2025

Accession no.
0001628280-25-050668
Filed
Nov 7, 2025
Trade date
Nov 5, 2025
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 14 non-derivative transactions and 3 derivative transactions. Open-market sales total $8.03M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Bate KennethCIK 0001210238Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 5, 2025Common StockMOption exerciseAcquired+5,470$9.45+$51,691.58,097Direct
Nov 5, 2025Common StockMOption exerciseAcquired+10,000$303.79+$3,037,90018,097Direct
Nov 5, 2025Common StockMOption exerciseAcquired+1,105$280.04+$309,444.219,202Direct
Nov 5, 2025Common StockSSaleDisposed−1,763$480.24F1−$846,663.1217,439Direct
Nov 5, 2025Common StockSSaleDisposed−3,259$481.13F2−$1,568,002.6714,180Direct
Nov 5, 2025Common StockSSaleDisposed−1,284$482.41F3−$619,414.4412,896Direct
Nov 5, 2025Common StockSSaleDisposed−2,069$483.41F4−$1,000,175.2910,827Direct
Nov 5, 2025Common StockSSaleDisposed−1,931$484.78F5−$936,110.188,896Direct
Nov 5, 2025Common StockSSaleDisposed−1,008$485.54F6−$489,424.327,888Direct
Nov 5, 2025Common StockSSaleDisposed−827$486.73F7−$402,525.717,061Direct
Nov 5, 2025Common StockSSaleDisposed−2,775$487.49F8−$1,352,784.754,286Direct
Nov 5, 2025Common StockSSaleDisposed−696$489.09F9−$340,406.643,590Direct
Nov 5, 2025Common StockSSaleDisposed−933$489.95F10−$457,123.352,657Direct
Nov 5, 2025Common StockSSaleDisposed−30$490.98F11−$14,729.42,627Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Nov 5, 2025Common StockMOption exerciseDisposed−5,470$0.00$00Direct
Nov 5, 2025Common StockMOption exerciseDisposed−10,000$0.00$00Direct
Nov 5, 2025Common StockMOption exerciseDisposed−1,105$0.00$00Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $479.66 to $480.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.

Referenced by the price of 1 transaction in Table I.

F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $480.71 to $481.68, inclusive.

Referenced by the price of 1 transaction in Table I.

F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $481.84 to $482.71, inclusive.

Referenced by the price of 1 transaction in Table I.

F4

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $483.00 to $483.92, inclusive.

Referenced by the price of 1 transaction in Table I.

F5

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $484.02 to $485.015, inclusive.

Referenced by the price of 1 transaction in Table I.

F6

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $485.10 to $486.04, inclusive.

Referenced by the price of 1 transaction in Table I.

F7

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $486.10 to $486.99, inclusive.

Referenced by the price of 1 transaction in Table I.

F8

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $487.13 to $488.09, inclusive.

Referenced by the price of 1 transaction in Table I.

F9

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $488.74 to $489.49, inclusive.

Referenced by the price of 1 transaction in Table I.

F10

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $489.74 to $490.7125, inclusive.

Referenced by the price of 1 transaction in Table I.

F11

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $490.7625 to $491.42, inclusive.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)